SCHEMBL21569552

SCHEMBL21569552

Cc1ccc2c([SH](=O)=O)c[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 3/20 0.51
▸ NR4A2 P43354 2/20 0.49
▸ IDO1 P14902 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HTR1D P28221 2/20 0.40
▸ PCSK9 Q8NBP7 1/20 0.39
▸ KIF11 P52732 1/20 0.39
▸ PIM3 Q86V86 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NR3C1 P04150 1/20 0.37
▸ MITF O75030 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569551 0.78 CYP2A6 (0.54) HTR2AIDO1PIM3SLC6A4ADRA1A
SCHEMBL21569556 0.78 GPR84 (0.53) HTR2AIDO1HTR1A
SCHEMBL20354743 0.78 IMPDH2 (0.46) HTR2AMEN1KMT2AKIF11KDM4E
SCHEMBL20354815 0.78 GPR84 (0.53) HTR2ANR4A2IDO1LMNASLC6A4
SCHEMBL20354724 0.77 HTR2A (0.56) HTR2AMEN1KMT2AHTR1DKDM4E
SCHEMBL26181019 0.75 HTR2A (0.51) HTR2ANR4A2IDO1MEN1KMT2A
SCHEMBL29555842 0.74 ATM (0.56) HTR2ANR4A2IDO1MEN1KMT2A
SCHEMBL12352 0.74 ATM (0.56) HTR2ANR4A2IDO1MEN1KMT2A
SCHEMBL21569511 0.74 HSD17B10 (0.53) MEN1KMT2AKIF11HSD17B10MAPT
SCHEMBL20354802 0.73 HTR1D (0.40) HTR2AHTR1DHTR2CSLC6A4HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2022-05-31 — — US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 HTR2A 649/4885NR4A2 96/4885IDO1 108/4885
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 HTR2A 649/4885NR4A2 96/4885IDO1 108/4885
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 HTR2A 649/4885NR4A2 96/4885IDO1 108/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 HTR2A 649/4885NR4A2 96/4885IDO1 108/4885
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 HTR2A 649/4885NR4A2 96/4885IDO1 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback